Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 2/20 | 0.32 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | PDE1A | P54750 | 4/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31527135 | 0.92 | CYP4F2 (0.39) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL31527053 | 0.92 | CYP4F2 (0.39) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL30959562 | 0.87 | CYP4F2 (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL31527476 | 0.85 | CYP4F2 (0.39) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL30959464 | 0.83 | CYP4F2 (0.39) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL30959467 | 0.82 | CYP4F2 (0.41) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL20974775 | 0.82 | CYP4F2 (0.40) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL31527186 | 0.81 | RXRA (0.36) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL21195793 | 0.81 | CYP4F2 (0.45) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL30959367 | 0.81 | CYP4F2 (0.40) | CYP4F2CYP4A11RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709371-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4615847-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024233776-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| WO-2024103010-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC (US) | 2024-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | CYP4F2 4690/4885CYP4A11 4627/4885RXRA 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.